Thalia Therapeutics Plc

Healthcare GB THAT

0.56GBX
-0.015(2.61%)

Last update at 2026-06-11T13:39:00Z

Day Range

0.550.56

LowHigh

52 Week Range

0.351.00

LowHigh

Fundamentals

Previous Close 0.57
Market Cap4.07M
Volume339881
P/E Ratio-
Dividend Yield-%
Revenue TTM0.00707M
Revenue Per Share TTM-
Gross Profit TTM 0.00707M
Diluted EPS TTM-

Overview
Financials
Peer Comparison
Reports
Stock Research & News
Profile

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly
Date	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Income before tax	-1.22100M	-1.42500M	-1.19300M	-1.84300M
Minority interest	0.06M	0.00745M	0.00000M	-
Net income	-1.05900M	-1.26900M	-1.02900M	-1.54400M
Selling general administrative	0.55M	0.72M	0.62M	0.66M
Selling and marketing expenses	-	-	-	-
Gross profit	0.00728M	0.00195M	-	-
Reconciled depreciation	-	-	-	-
Ebit	-	-1.42417M	-1.42149M	-2.07956M
Ebitda	-1.22100M	-1.33500M	-1.19300M	-1.84300M
Depreciation and amortization	-	0.09M	0.23M	0.24M
Non operating income net other	-	-	-	-
Operating income	-1.22100M	-1.42500M	-1.19300M	-1.84300M
Other operating expenses	1.23M	1.43M	1.19M	1.84M
Interest expense	-	-	-	-
Tax provision	-0.10111M	-0.14782M	-0.16400M	-0.29827M
Interest income	-	0.00000M	0.00000M	0.00068M
Net interest income	-	0.00000M	0.00000M	0.00068M
Extraordinary items	-	-	-	-
Non recurring	-	-	-	-
Other items	-	-	-	-
Income tax expense	-0.10100M	-0.14800M	-0.16400M	-0.29800M
Total revenue	0.00728M	0.00195M	0.00000M	0.00000M
Total operating expenses	1.17M	1.43M	1.19M	1.84M
Cost of revenue	-	-	-	-
Total other income expense net	-	-	-	0.00068M
Discontinued operations	-	-	-	-
Net income from continuing ops	-1.11999M	-1.27678M	-1.02926M	-1.54435M
Net income applicable to common shares	-	-	-	-
Preferred stock and other adjustments	-	-	-	-

Breakdown	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly
Date	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total assets	0.78M	1.28M	2.17M	2.34M
Intangible assets	-	-	-	-
Earning assets	-	-	-	-
Other current assets	0.02M	0.01M	0.04M	0.00701M
Total liab	0.12M	0.08M	0.08M	0.21M
Total stockholder equity	0.65M	1.13M	2.09M	2.13M
Deferred long term liab	-	-	-	-
Other current liab	0.10M	0.07M	0.04M	0.03M
Common stock	1.58M	9.35M	9.21M	9.00M
Capital stock	1.58M	1.08M	0.94M	0.72M
Retained earnings	-10.39901M	-9.34127M	-21.92031M	-20.89105M
Other liab	-	-	-	-
Good will	0.00000M	0.06M	0.00000M	-
Other assets	-	-	-	-
Cash	0.63M	1.03M	1.92M	1.78M
Cash and equivalents	-	-	-	-
Total current liabilities	0.12M	0.08M	0.08M	0.21M
Current deferred revenue	-	-	-	-
Net debt	-0.62597M	-1.02711M	-1.91953M	-1.78402M
Short term debt	-	-	-	-
Short long term debt	-	-	-	-
Short long term debt total	-	-	-	-
Other stockholder equity	9.47M	1.02M	14.70M	13.95M
Property plant equipment	-	-	-	-
Total current assets	0.78M	1.21M	2.17M	2.34M
Long term investments	-	-	-	-
Net tangible assets	-	-	-	-
Short term investments	-	-	-	-
Net receivables	0.13M	0.18M	0.21M	0.55M
Long term debt	-	-	-	-
Inventory	-	-	-	-
Accounts payable	0.02M	0.02M	0.04M	0.18M
Total permanent equity	-	-	-	-
Noncontrolling interest in consolidated entity	-	-	-	-
Temporary equity redeemable noncontrolling interests	-	-	-	-
Accumulated other comprehensive income	0.11M	0.11M	0.10M	0.08M
Additional paid in capital	-	-	-	-
Common stock total equity	-	-	-	-
Preferred stock total equity	-	-	-	-
Retained earnings total equity	-	-	-	-
Treasury stock	-	-	-	-
Accumulated amortization	-	-	-	-
Non currrent assets other	-	-	-	-
Deferred long term asset charges	-	-	-	-
Non current assets total	0.00000M	0.06M	0.00000M	0.00000M
Capital lease obligations	-	-	-	-
Long term debt total	-	-	-	-

Breakdown	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly
Date	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Investments	-	-	-	-
Change to liabilities	-	-	-	-
Total cashflows from investing activities	-	0.00078M	-	-
Net borrowings	-	-	-	-
Total cash from financing activities	0.57M	0.32M	0.96M	0.00068M
Change to operating activities	-	-	-	-
Net income	-1.11999M	-1.26933M	-1.02926M	-1.54435M
Change in cash	-0.40114M	-0.89242M	0.14M	-1.77155M
Begin period cash flow	1.03M	1.92M	1.78M	3.56M
End period cash flow	0.63M	1.03M	1.92M	1.78M
Total cash from operating activities	-0.97150M	-1.20910M	-0.82826M	-1.77223M
Issuance of capital stock	0.63M	0.35M	1.05M	0.00000M
Depreciation	-	-	-	-
Other cashflows from investing activities	-	-	-	-
Dividends paid	-	-	-	-
Change to inventory	-	-	-	-
Change to account receivables	-0.00946M	0.04M	-0.03731M	0.01M
Sale purchase of stock	-	-	-	-
Other cashflows from financing activities	-0.05964M	-0.03410M	-0.09023M	0.00068M
Change to netincome	-	-	-	-
Capital expenditures	0.00000M	0.00000M	0.00000M	0.00000M
Change receivables	-	-	-	-
Cash flows other operating	-	-	-	-
Exchange rate changes	-	-	-	-
Cash and cash equivalents changes	-	-	-	-
Change in working capital	0.03M	0.05M	-0.17215M	0.05M
Stock based compensation	0.00739M	0.00343M	0.02M	0.02M
Other non cash items	0.11M	0.00873M	0.35M	-0.29894M
Free cash flow	-0.97150M	-1.20910M	-0.82826M	-1.77223M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company	Change (GBX)	Price (GBX)	Trailing PE (x)	Forward PE (x)	Price Sales TTM (x)	Price to Book Value (x)	Enterprise Value to Revenue (x)	Enterprise Value to EBITDA (x)
THAT Thalia Therapeutics Plc	-0.015 2.61%	0.56	-	-	575.98	2.12	285.55	-1.8199
GNS Genus PLC	28.00 1.29%	2198.00	36.08	26.18	2.53	3.46	2.92	15.38
ONT Oxford Nanopore Technologies Ltd	2.00 1.67%	122.00	-	-	4.71	2.50	4.23	-8.8899
OXB Oxford BioMedica PLC	7.00 1.15%	617.00	-	208.33	4.05	7.60	4.42	308.96
AVCT Avacta Group PLC	- -%	68.50	-	-	2849.46	1929.84	2525.51	-12.0368

Reports Covered

View All

Profile

Thalia Therapeutics Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom. It develops Nuvec, a silica nanoparticle delivery system, which has an irregular surface structure that traps and protects siRNA/RNA/DNA; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The company also engages in the development of N4 101, an orally delivered inflammation inhibitor which is in the pre-clinical development for treatment of inflammatory bowel disease; and ECP105 for the prevention of ocular scarring. Thalia Therapeutics Plc was formerly known as N4 Pharma Plc and changed its name to Thalia Therapeutics Plc in March 2026. Thalia Therapeutics Plc was incorporated in 1979 and is based in Chellaston, the United Kingdom.

Thalia Therapeutics Plc

Weston house, Chellaston, United Kingdom, DE73 5UJ

https://www.thaliatx.com
Employees : 4

Key Executives

Name	Title	Year Born
Mr. Luke Sebastian Cairns	Executive Director	1978
Dr. David Horn Solomon M.D.	CEO & Director	1960
Rob Harris	Head of CMC Development	NA
Dr. Fiona McLaughlin FSB, Ph.D.	Head of Research & Development	1970
Mr. Mark Edbrooke Ph.D.	Head of Strategy	NA
Dr. Margaret Courtney Ph.D.	Head of Chemistry, Manufacturing & Controls	NA
Dr. Andrew Leishman	Consultant	NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.